Pharmacists, pharmaceutical manufacturers, and conflicts of interest

American Journal of Health-System Pharmacy

Volumn 62, Issue 17, 2005, Pages 1827-1832

  Banks, David ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

UNCLASSIFIED DRUG;

DRUG INDUSTRY; DRUG MANUFACTURE; ETHICS; GOVERNMENT; HUMAN; NOMENCLATURE; NOTE; PHARMACIST; PHARMACY BENEFIT MANAGER; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROFESSIONAL PRACTICE; TRUST; UNCERTAINTY;

EID: 24144449933     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.2146/ajhp040504     Document Type: Note

References (48)

1. Cassell D. How manufacturers view pharmacists: drug company executives think pharmacists are a growing force to be reckoned with, an exclusive survey finds, www.drugtopics.com/drugtopics/ content/printContentPopup.jsp? id117795 (accessed 2005 Jun 16).
2. Davis M, Stark A, eds. Conflict of interest in the professions. Oxford, England: Oxford Univ. Press; 2001.
3. Beauchamp TL, Childress JF. Principles of biomedical ethics. 5th ed. Oxford, England: Oxford Univ. Press; 2001:312.
4. MacDonald M. Conflicts of interest. www.ethics.ubc.ca/people/mcdonald/ conflicthtm (accessed 2005 Jun16).
5. Latham SR. Conflict of interest in medical practice. In: Davis M, Stark A, eds. Conflict of interest in the professions. Oxford, England: Oxford Univ. Press; 2001:283.
6. Toulmin S. Divided loyalties and ambiguous relationships. Soc Sci Med. 1986; 23:783-7.
7. Dana J, Loewenstein G. A social science perspective on gifts to physicians from industry. JAMA. 2003; 290:252-5.
8. Hall ML. J Health Polit Policy Law. 2001; 26:1131-44.
9. Murray TH. Divided loyalties for physicians: social context and moral problems. Soc Sci Med. 1986; 23:827-32.
10. Jewesson PJ. Pharmacists and potential conflicts of interest - doing the right thing. www.informedpharmacotherapy. com/Issue11/toc.htm (accessed 2005 Jun 20).
11. Clark E. The want makers: the world of advertising: how they make you buy. New York: Viking Penguin; 1989.
12. Katz D, Caplan AL, Merz JF. All gifts large and small. Toward an understanding of the ethics of pharmaceutical industry gift-giving. Am J Bioethics. 2003; 3(3):39-46.
13. Murphy S. Gifts seen effective by drug company reps. Boston Globe. 2002; Nov 17.
14. Berger JT. Pharmaceutical industry influences on physician prescribing: gifts, quasi-gifts, and patient-directed gifts. Am J Bioethics. 2003; 3(3):56-7.
15. Harris G. As doctor writes prescription, drug company writes a check. N Y Times. 2004; Jun 27:1.
16. Latham SR. Conflict of interest in medical practice. In: Davis M, Stark A, eds. Conflict of interest in the professions. Oxford, England: Oxford Univ. Press; 2001:295.
17. Haddad A. Trustworthiness and professional ethics. J Am Pharm Assoc. 2002; 42:540-1.
18. American Association of Colleges of Pharmacy. Entry level, curricular outcomes, curricular content and educational process. Background paper II. www.aacp.org/Docs/MainNavigation/ EducationalResources/3587_ BackgroundPaper2.pdf (accessed 2005 Jun 20).
19. Hasegawa GR. Full disclosure. Am J Health-Syst Pharm. 2002; 59:1835. Editorial.
20. Zoloth AM. The need for ethical guidelines for relationships between pharmacists and the pharmaceutical industry. Am J Hosp Pham. 1991; 48:551-2.
21. Kennelly W. Pharmacists should not accept gifts from industry. Am J Hosp Pharm. 1992; 49:1108.
22. Haines ST, Dumo P. Relationships between the pharmaceutical industry and pharmacy practitioners: undue influence? Am J Health-Syst Pharm. 2002; 59:1871-4.
23. Brubaker B. Drug industry adopts guidelines on giveaways to doctors. Wash Post. 2002; Apr 20:E3.
24. Lexchin J. Voluntary self-regulatory codes: what should we expect? Am J Bioethics. 2003; 3(3):49-50.
25. Agovino T. Drug cos. reform marketing to docs. Seattle Post-Intelligencer. 2002; Oct 2.
26. Kusserow RP. Promotion of prescription drugs through payments and gifts. Washington, DC: Department of Health and Human Services; 1991.
27. Foley LA. Drug marketing from an Office of Inspector General enforcement perspective. Food Drug Law J. 1995; 50:309.
28. 42 U.S.C. Sec 1320a-7b(b).
29. U.S. Department of Justice. TAP Pharmaceutical Products Inc. and seven others charged with health care crimes; company agrees to pay $875 million to settle charges, www.usdoj.gov/opa/ 2001/October/513civ.htm (2005 Jun 20).
30. Office of Inspector General. Draft OIG compliance program guidance for pharmaceutical manufacturers. Fed Regist. 2002; 67:62057-67.
31. Pear R. Drug makers battle plan to curb rewards for doctors. N Y Times. 2002; Dec 26.
32. Freudenheim M. Documents detail big payments by drug makers to sway sales. N Y Times. 2003; Mar 13:C1.
33. Freudenheim M. Payments by managers of drug plans face scrutiny. N Y Times. 2003; Dec 11.
34. PBM pharmacists' obligation is to patients, not company, prosecutor says. FDC Rep. 2003; 65(46):24.
35. Poirier TI, Giannetti V, Giudici RA. Pharmacists' and physicians' attitudes toward pharmaceutical marketing practices. Am J Hosp Pharm. 1994; 51:278-81.
36. Relman AS, Angell M. America's other drug problem: how the drug industry distorts medicine and politics. New Republic. 2002; Dec 16:27-41.
37. Katz MJ, Feinstein R. FTC testifies on competition in the U.S. pharmaceutical industry. Activities involving brand and generic patient settlement case detailed. www.ftc.gov/opa/2001/05/drugtest.htm (accessed 2005 Jun 20).
38. National Association of Attorneys General. States sue makers of breast cancer drug. Suit filed to protect patients, state dollars, www.naag.org/news/ pr-20020604-taxol.php (accessed 2005 Jun 20).
39. Stewart KA, Neumann PJ. FDA actions against misleading or unsubstantiated economic and quality-of-life promotional claims: an analysis of warning letters and notices of violation. Value Health. 2002; 5:389-96.
40. Food and Drug Administration Division of Drug Marketing, Advertising, and Communications. Warning letters and untitled letters to pharmaceutical companies, 2002. www.fda.gov/cder/warn/ warn2002.htm (accessed 2005 Jun 20).
41. Emery T. Suit alleges promotion of drug skirted U.S. law. Phila Inquirer. 2003; Aug 12.
42. Families USA. Games the Rx drug industry plays. www.familiesusa.org/site/ DocServer/Leadstorypdf?docID=331 (accessed 2005 Jun 20).
43. Wexler C. Prescription for power, how brand-name drug companies prevailed over consumers in Washington. www.commoncause.org (accessed 2005 Jun 20).
44. Committee on Government Reform, U.S. House of Representatives. Prescription drug pricing in the United States, drug companies profit at the expense of older Americans. http://democrats. reform.house.gov/Documents/ 20040629104049-62473.pdf (accessed 2005 Jun 20).
45. Pear R. Investigators say drug makers repeatedly overcharged. N Y Times. 2004; Jun 30:A19.
46. Kramer TA. A plea for biased information. www.medscape.com/viewarticle/ 468112 (accessed 2005 Jun 20).
47. Hess E. Am Wkly. 1955; Apr 24.
48. Banks D, Miller N. Pharmacist attitudes regarding relationships with pharmaceutical manufacturers. Unpublished manuscript.